Lilly Is Betting On Byetta LAR
CEO Lechleiter is “confident” that clinical data expected this quarter on Lilly’s follow-on Byetta LAR will overcome FDA concerns over Byetta.
CEO Lechleiter is “confident” that clinical data expected this quarter on Lilly’s follow-on Byetta LAR will overcome FDA concerns over Byetta.